B
CPIX icon

Bailard’s Cumberland Pharmaceuticals CPIX Stock Holding History

Bailard’s Portfolio CPIX Stock Details CPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160K Buy
+24,624
New +$118K ﹤0.01% 745
2020
Q1 		– Sell
-11,816
Closed -$61K – 473
2019
Q4 		$61K Hold
11,816
– – ﹤0.01% 533
2019
Q3 		$70K Sell
11,816
-2,700
-19% -$15K ﹤0.01% 523
2019
Q2 		$92K Buy
+14,516
New +$88K 0.01% 531

Other funds holding CPIX

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Bailard's CPIX Position: Q2 2026 in Review

Bailard opened a new position in Cumberland Pharmaceuticals (CPIX) in Q2 2026: 24,624 shares worth $160K. The stake represents ﹤0.01% of the portfolio and ranks #745 among its holdings. This is a return to the name: Bailard previously reported a position in CPIX as recently as Q4 2019.

Bailard first reported a position in CPIX in Q2 2019 and has held it in 4 quarters since. 32 funds tracked by Wall St. Rank hold CPIX as of Q2 2026.

  • Bailard held 24,624 shares of Cumberland Pharmaceuticals worth $160K as of Q2 2026.
  • Cumberland Pharmaceuticals was a new Bailard position in Q2 2026.
  • Cumberland Pharmaceuticals made up ﹤0.01% of Bailard's portfolio in Q2 2026, its #745 holding.
  • Bailard first reported a position in Cumberland Pharmaceuticals in Q2 2019 and has held it in 4 quarters since.
  • 32 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q2 2026.

Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.